Loading stock data…
LQDA
$64.01+0.11 (+0.17%)
After Hours$62.88-1.13 (-1.77%)· Last close Jun 9
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Liquidia Corporation in the Healthcare sector is trading at $64.01. Wall Street consensus targets $66.12 (8 analysts), implying a +3.3% move over the next 12 months. The stock is currently near its 52-week high of $66.78, remaining 80.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$64.01
Potential Downside
0%
Whystock Fair Value$64.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.54%
Volume
Today's trading volume
1.61M
Recent News
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
How YUTREPIA Profitability and Patent Tailwinds At Liquidia (LQDA) Has Changed Its Investment Story
In recent days, Liquidia Corporation reported its third consecutive profitable quarter driven by continued sales growth of its inhaled treprostinil therapy YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, alongside progress in its L606 Phase 3 Re-Spire trial. Investor attention has also focused on a Supreme Court ruling viewed as supportive of Liquidia’s position in key patent litigation, which could meaningfully influence the...
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.
4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gains and solid volume.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.